Prof. Dr. B. Canaud: CONVINCE – the breakthrough trial for high-volume HDF?
614 بار بازدید -
12 ماه پیش
-
At the 60th ERA Congress
At the 60th ERA Congress in Milan, Prof. Peter Blankestijn revealed remarkable findings from the CONVINCE trial. This groundbreaking study proves that high-volume Hemodiafiltration (HV-HDF) offers significant clinical advantages for patient survival in comparison to more commonly used high-flux Hemodialysis.
Prof. Dr. Bernard Canaud is part of the trial's scientific committee and expressed enthusiasm for implementing HV-HDF as a therapeutic option for dialysis patients.
CONVINCE STUDY
This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 754803.
Do not miss the chance to discover the Life/ nephrology campus and register now on https://www.nephrologycampus.com/
The Life/ nephrology campus is empowered by Fresenius Medical Care Deutschland GmbH.
Prof. Dr. Bernard Canaud is part of the trial's scientific committee and expressed enthusiasm for implementing HV-HDF as a therapeutic option for dialysis patients.
CONVINCE STUDY
This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 754803.
Do not miss the chance to discover the Life/ nephrology campus and register now on https://www.nephrologycampus.com/
The Life/ nephrology campus is empowered by Fresenius Medical Care Deutschland GmbH.
12 ماه پیش
در تاریخ 1402/05/12 منتشر شده
است.
614
بـار بازدید شده